You are here

Novartis

Novartis Inks Potential $1.3B Contract with Korean Biotech for Small Molecule

BioSpace

Tue, 11/7/23 - 10:05 am

Chong Kun Dang Pharmaceutical

small molecule drugs

FDA approves Novartis Cosentyx as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade

Yahoo Finance

Wed, 11/1/23 - 10:14 pm

Atrasentan data backs up Novartis’ $3.5bn Chinook deal

Pharmaphorum

Mon, 10/30/23 - 10:21 am

IgA nephropathy

Chinook Therapeutics

Tricks and Treats as Biopharma’s Q3 Earnings Season Gets Underway

BioSpace

Sun, 10/29/23 - 08:53 pm

Bristol Myers Squibb

Novartis claims ex-staffer jumped to Takeda with 'thousands' of sensitive files

Fierce Pharma

Thu, 10/26/23 - 10:52 pm

Novartis Beats Earnings Estimate in Q3, Raises Full-Year Guidance

BioSpace

Tue, 10/24/23 - 07:46 pm

Novartis Builds Case for Earlier Prostate Cancer Treatment with Phase III Data

BioSpace

Tue, 10/24/23 - 09:54 am

prostate cancer

radiopharmaceuticals

Novartis expats detail their health-tech spinoff DatosX

Medical Marketing and Media

Wed, 10/11/23 - 11:44 pm

Novartis cuts depression study, nearly erasing $210M Cadent acquisition from pipeline

Fierce Biotech

Tue, 10/10/23 - 11:36 am

Cadent Therapeutics

major depressive disorder

Novartis-backed AstronauTx heads off for Alzheimer's mission with $61M series A

Fierce Biotech

Mon, 10/9/23 - 11:12 am

Alzheimer's disease

Novartis Wins FDA Approval for Intravenous Cosentyx Formulation

BioSpace

Mon, 10/9/23 - 10:14 am

ankylosing spondylitis

psoriatic arthritis

non-radiographic axial spondyloarthritis

Novartis' Sandoz dips on debut after lower than expected valuation

Reuters

Wed, 10/4/23 - 09:43 am

Novartis eyes accelerated FDA approval for iptacopan across multiple indications

Clinical Trials Arena

Mon, 10/2/23 - 10:14 am

clinical trials

IgA nephropathy

Adlai Nortye IPO gives old Novartis cancer drug new life

BioPharma Dive

Fri, 09/29/23 - 10:22 am

head and neck cancer

Novartis confirms Sandoz spin-off for October 4, 2023

Reuters

Mon, 09/25/23 - 07:45 pm

Novartis eyes first-line use of Lutathera after trial win

Pharmaphorum

Mon, 09/25/23 - 11:41 am

clinical trials

neuroendocrine tumors

FDA Regulatory Gauntlet Isn’t Getting Any Easier, Just Ask These Companies

BioSpace

Sun, 09/24/23 - 08:52 pm

ARS Pharmaceuticals

Novartis hit with another serious drug marketing breach, this time for multiple sclerosis therapy Mayzent

Fierce Pharma

Thu, 09/21/23 - 10:36 am

pharma marketing

BeiGene to go solo with cancer drug after Novartis deal termination

Yahoo/Reuters

Tue, 09/19/23 - 10:30 am

Bausch + Lomb seeks funding for eye drug acquisition from Novartis

BioPharma Dive

Wed, 09/13/23 - 11:32 am

Pages